Half Year 2025 Circio Holding ASA Earnings Call and R&D Update Transcript
Key Points
- Circio Holding ASA (FRA:TA50) has secured stable cash flow through funds raised in the warrant exercise and the Atlas facility, ensuring operations are funded until the end of 2025 with potential extensions into 2026.
- The company has entered seven R&D collaborations in the first half of the year, enhancing its business development efforts.
- Significant progress has been made on the circVec platform, demonstrating a 10 to 40-fold improvement in AAV gene therapy activity, potentially reducing toxicity and manufacturing costs.
- The circVec technology shows promise in multiple disease areas, with a focus on gene therapy using AAVs and a cell therapy program utilizing circVec DNA vectors.
- Circio has reduced its outstanding bonds from NOK35 million to less than NOK10 million, strengthening its financial position and reducing financial risk.
- The high dose levels required for AAV gene therapies pose challenges, including increased toxicity and manufacturing costs, which have affected other companies in the field.
- Market conditions remain challenging, impacting investor behavior and decisions, which could affect future financing efforts.
- Despite strong interest, discussions with investors have seen moving goalposts, with demands for more data, complicating financing efforts.
- The company operates on a tight budget of less than NOK4 million per month, limiting the scope of its operations and potential for faster progress.
- Some collaborations and business development activities remain confidential, and not all collaborations are expected to succeed, which could impact future growth.
Welcome to Circio. My name is Erik Digman Wiklund. I am the CEO. Today, we are presenting our first half-year results as well as an update on our circVec R&D program. Together with me, I have CFO, Lubor Gaal; as well as Thomas Hansen, CTO.
I will begin with a short highlights session as well as an update on relevant market conditions. Importantly, during the first half of the year, we've been operating under funds raised in the warrant exercise end of 2024 as well as the Atlas facility, and this has enabled us to have a stable cash flow into the company. We've also extended the financing commitment with Atlas. This secures capital to fund our operations until end of the year with an option for further extensions into 2026.
On business development, we have been very active. We entered seven R&D collaborations during first half of the year, and Lubor will come back to these in his presentation. And importantly, we made substantial progress on our circVec platform. We have now showed convincing strong proof of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
